Axial: targeting gut microbe metabolites for CNS disorders
Why Axial thinks the gut microbiome is key to Parkinson's disease and autism
Microbiome play Axial is using small molecules to treat the gut end of the gut-brain axis for Parkinson's disease and autism.
Co-founder and CEO David Donabedian told BioCentury that Axial Biotherapeutics Inc. believes that the microbiome is driving the disease pathology in these indications from the gut.
The company was founded in 2016 based on research from co-founder Sarkis Mazmanian that indicated gut microbiome manipulation could treat the indications, prompting Longwood Fund, where